Integrated Diagnostics boosts 2025 profits on strong growth and margin gains

Integrated Diagnostics Holdings ( (GB:IDHC) ) has shared an announcement.

Integrated Diagnostics Holdings reported strong full-year 2025 results, with revenue rising 37% to EGP 7.9 billion, driven by an 11% increase in test volumes and a 24% rise in average revenue per test. Profitability improved sharply as gross margin expanded to 42.7% and EBITDA margin to 34.9%, underpinned by tighter cost controls, scale efficiencies and disciplined SG&A spending.

Net profit grew 29% to EGP 1.3 billion, while adjusted net profit advanced 79%, highlighting robust underlying performance despite prior-year FX gains and geopolitical headwinds, particularly in Sudan. The company expanded its network to 767 branches, integrated the Cairo Ray for Radiotherapy acquisition, increased tests to 43.5 million and raised revenue per patient by 31%, while maintaining a net cash position and declaring a measured dividend to balance shareholder returns with funding for future growth.

More about Integrated Diagnostics Holdings

Integrated Diagnostics Holdings is a leading diagnostics services provider operating across Egypt, Jordan, Nigeria, Saudi Arabia and Sudan, offering laboratory tests, radiology and radiotherapy. The group targets both corporate and walk-in patients, with a strategy focused on expanding its branch network and building a fully integrated diagnostics platform in key emerging markets.

Average Trading Volume: 146,337

Technical Sentiment Signal: Buy

Current Market Cap: $372M

See more insights into IDHC stock on TipRanks’ Stock Analysis page.